

CURRICULUM VITAE

ARNOLD S. MONTO, M.D.

Thomas Francis Jr. Collegiate Professor of Public Health
Professor of Epidemiology

CONTACT INFORMATION

University of Michigan
School of Public Health
Department of Epidemiology
Room M5146, SPH II
1415 Washington Heights
Ann Arbor, Michigan 48109-2029
Phone: (734) 764-5453
FAX: (734) 936-2084
Email: asmonto@umich.edu

EDUCATION

Cornell University Medical College New York, NY	M.D.	1958
Cornell University Ithaca, NY	B.A.	1954

POSITIONS

Intern and Assistant Resident in Medicine, Vanderbilt University Hospital, 1958-60
USPHS Post Doctoral Fellow in Infectious Diseases, Stanford Medical Center, 1960-1962
Staff Member, Virus Diseases Section, Middle America Research Unit, National Institute of Allergy and Infectious Diseases, 1962-1965
Research Associate, Assistant Professor, Associate Professor, and Professor, Department of Epidemiology, School of Public Health, The University of Michigan, 1965-present
Thomas Francis Jr. Collegiate Professor of Public Health, 2010-present

PROFESSIONAL EXPERIENCE:

Visiting Scientist, Clinical Research Centre, Northwick Park Hospital, Harrow, England, 1976
Scholar-in-Residence, National Academy of Sciences (Board on Science and Technology for International Development) and Institute of Medicine, 1983-1984

Advisor, Division of Communicable Diseases, World Health Organization, Geneva, Switzerland, 1986-1987

Chairman, Department of Population Planning and International Health and *Director*, Center for Population Planning and International Health, University of Michigan, 1993-1996

Director, University of Michigan Bioterrorism Preparedness Initiative, 2002-2004

Director, The Israel Public Health Initiative, University of Michigan, 2014 - present

HONORS

Career Development Award, NIH

Pulmonary Diseases Advisory Committee, NHLBI

National Advisory Allergy and Infectious Diseases Council, 1989-1993

President, American Epidemiological Society, 2004-05

Alexander Fleming Lifetime Achievement Award, Infectious Diseases Society of America, 2009

Thomas Francis Jr. Lectureship, University of Michigan 2010

Charles Merieux Award, National Foundation for Infectious Diseases, 2012

Monto Award for Epidemiology Established at CDC Influenza Division, 2015

PROFESSIONAL ORGANIZATIONS

American Epidemiological Society

American Association for the Advancement of Science

American Public Health Association

Infectious Diseases Society of America (Fellow)

International Epidemiological Association

Society for Epidemiologic Research

LICENSURE

Medical Doctor, Michigan permanent I.D. #126731

Diplomat, American Board of Medical Microbiology

Diplomat, American College of Epidemiology

CURRENT GRANT SUPPORT

Household Studies of Influenza and Other Respiratory Viruses

Role: Co-Principal Investigator

Date: 8/20/2012 - 7/31/2017

Funder: National Institutes of Health (NIH)

This grant allows expansion of the household study to include identification of other respiratory viruses and analysis of immunologic responses to influenza infection and vaccination.

US Platform to Measure Influenza Vaccine Effectiveness Against Laboratory-confirmed Influenza-associated Hospitalizations

Role: Principal Investigator

Date: 8/01/2015 - 7/31/2020

Funder: U.S. Centers for Disease Control and Prevention (CDC)

This cooperative agreement is intended to determine on an annual basis the effectiveness of influenza vaccine by collecting and comparing data on laboratory confirmed outpatient influenza cases and controls. Household study funded as an optional component.

US Influenza Vaccine Effectiveness (VE) Network

Role: Principal Investigator

Date: 8/01/2016 – 7/31/2021

Funder: National Center for Immunization and Respiratory Diseases (NCIRD)

This cooperative agreement is a five site network intended to determine the effectiveness of influenza vaccine in preventing medically attended illnesses on an annual basis.

SELECTED RECENT SERVICE

International and National

Member, Vaccines and Related Biologic Products Advisory Committee, FDA 2016-2020

Member, President's Council of Advisors on Science and Technology 2009 – H1N1 Working Group, 2009

WHO Emergency Committee, Influenza Pandemic 2009-2010

Board Member, European Scientific Working Group on Influenza, 2009-present

Member, Scientific and Technical Advisory Group, World Health Organization, Global Influenza Programme, 2009- present

Advisory Board, Emory University Center for Excellence in Influenza Research and Surveillance, 2008-present

Pandemic Influenza Task Force, Infectious Disease Society of America, 2007- present

Scientific Committee, Merieux Foundation, 2007-present

Co-chair Neuraminidase Inhibitor Susceptibility Network, 2006-2013

Co-chair, Infectious Disease Society of America Meetings Seasonal and Pandemic Influenza, 2006-2010
World Health Organization Pandemic Influenza Task Force, 2006-2007
Institute of Medicine Committee on Modeling Community Containment for Pandemic Influenza, 2006
Briefing on Pandemic Influenza, Health Committees of House of Commons and Senate, Ottawa, 2006
Briefing on Pandemic Influenza, State Department, Washington, DC, 2006
Moderator, NIH Meeting on Antivirals for Pandemics, 2006
Pandemic Advisory Group, European Commission, Brussels, 2005
Consultant, DARPA, Department of Defense, Predicting Health and Disease Workshop, 2005
Advisor, Defense Threat Reduction Agency, Department of Defense, 2005-present

PUBLICATIONS

1. Monto AS. The liver in ulcerative disease of the intestinal tract: Functional and anatomic changes. *Ann of Int Med.* 1959; 50:1385-94.
2. Vosti KL, Monto AS and Rantz LA. The importance of sample size in studies based upon the serologic classification of *Escherichia coli*. *Proc Soc Exp Biol Med.* 1962; 111:201-4.
3. Monto AS and Rantz LA. The development and character of bacteriuria in pregnancy. *Ann Int Med.* 1963; 59:186-93.
4. Vosti KL, Monto AS, Older JJ and Rantz LA. The serologic specificity of crude and purified antigen extracts of *Escherichia coli* in hemagglutination reactions with rabbit and human antisera. *J Immun.* 1964; 93:199-204.
5. Vosti KL, Goldberg LM, Monto AS and Rantz LA. Host-parasite interaction in patients with infections due to *Escherichia coli*. I. The serogrouping of *E. coli* from intestinal and extraintestinal sources. *J Clin Invest.* 1964; 43:2377-85.
6. Monto AS and Rantz LA. Classification of so-called paracolonic bacilli isolated from urinary tract infection. *J Lab Clin Med.* 1965; 65:64-70.
7. Vosti KL, Monto AS, Rantz LA. Host-parasite interaction in patients with infections due to *Escherichia coli* II Serologic response of the host. *J Lab Clin Med.* 1965 Oct;66(4):613-26. PubMed PMID: 4954172.
8. Monto AS, Olazabal F Jr. Asian influenza in the Panama Canal zone: isolation of a virus variant and protective effect of a vaccine containing A2/Japan/305/57. *Am J Epidemiol.* 1966 Jan;83(1):101-12. PubMed PMID: 5910213.
9. Monto AS, Johnson KM. Serologic relationships of the B632 and ECHO-28 rhinovirus strains. *Proc Soc Exp Biol Med.* 1966 Feb;121(2):615-9. PubMed PMID: 4286797.
10. Monto AS, Johnson KM. A community study of respiratory infections in the tropics I Description of the community and observations on the activity of certain respiratory agents. *Am J Epidemiol.* 1967 Jul;86:78-92. PubMed PMID: 4951566.
11. Monto AS, Johnson KM. A community study of respiratory infections in the tropics II The spread of six rhinovirus isolates within the community. *Am J Epidemiol.* 1968 Jul;88:55-68. PubMed PMID: 4298480.
12. Monto AS. A community study of respiratory infections in the tropics 3 Introduction and transmission of infections within families. *Am J Epidemiol.* 1968 Jul;88:69-79. PubMed PMID: 4298481.

13. Monto AS, Johnson KM. Respiratory infections in the American tropics. *Am J Trop Med Hyg.* 1968 Nov;17:867-74. PubMed PMID: 4302276.
14. Monto AS. Prevalence of antistreptolysin O in young Panamanians. *Public Health Rep.* 1969 Jan;84:77-80. PubMed PMID: 4975340; PubMed Central PMCID: PMC2031429.
15. Monto AS, Davenport FM, Napier JA, Francis T Jr. Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. *Bull World Health Organ.* 1969;41(3):537-42. PubMed PMID: 5309469; PubMed Central PMCID: PMC2427727.
16. Francis T, Monto AS. Letters to the editor. *Am J Public Health Nations Health.* 1969 Apr;59(4):589. PubMed PMID: 18018250; PubMed Central PMCID: PMC1226466.
17. Monto AS, Cavallaro JJ, Brown GC. Attenuated rubella vaccination in families: observations on the lack of fluorescent antibody response and on the use of blood collected on filter paper discs in the hemagglutination-inhibition test. *J Lab Clin Med.* 1969 Jul;74(1):98-102. PubMed PMID: 4892624.
18. Monto AS, Davenport FM, Napier JA, Francis T Jr. Modification of an outbreak of influenza in Tecumseh, Michigan by vaccination of schoolchildren. *J Infect Dis.* 1970 Jul-Aug;122(1):16-25. PubMed PMID: 5433709.
19. Monto AS, Cavallaro JJ, Keller JB. Seasonal patterns of acute infection in Tecumseh, Mich. *Arch Environ Health.* 1970 Sep;21(3):408-17. PubMed PMID: 4323374.
20. Monto AS, Cavallaro JJ, Whale EH. Frequency of arthralgia in women receiving one of three rubella vaccines. *Arch Intern Med.* 1970 Oct;126(4):635-9. PubMed PMID: 4918712.
21. Cavallaro JJ, Monto AS. Community-wide outbreak of infection with a 229E-like coronavirus in Tecumseh, Michigan. *J Infect Dis.* 1970 Oct;122(4):272-9. PubMed PMID: 5504709.
22. Monto AS, Napier JA, Metzner HL. The Tecumseh study of respiratory illness I Plan of study and observations on syndromes of acute respiratory disease. *Am J Epidemiol.* 1971 Sep;94(3):269-79. PubMed PMID: 5093655.
23. Monto AS, Cavallaro JJ. The Tecumseh study of respiratory illness II Patterns of occurrence of infection with respiratory pathogens, 1965-1969. *Am J Epidemiol.* 1971 Sep;94(3):280-9. PubMed PMID: 4328569.
24. Monto AS, Lim SK. The Tecumseh study of respiratory illness 3 Incidence and periodicity of respiratory syncytial virus and *Mycoplasma pneumoniae* infections. *Am J Epidemiol.* 1971 Sep;94(3):290-301. PubMed PMID: 4328570.
25. Davenport FM, Monto AS. Practical considerations in the diagnosis of myxovirus infections. *Am J Clin Pathol.* 1972 Jun;57(6):777-82. PubMed PMID: 4337371.
26. Cavallaro JJ, Monto AS. HL cells, a sensitive line for the isolation and propagation of respiratory syncytial virus. *Proc Soc Exp Biol Med.* 1972 Jun;140(2):507-10. PubMed PMID: 4338798.
27. Monto AS, Cavallaro JJ. The Tecumseh study of respiratory illness IV Prevalence of rhinovirus serotypes, 1966-1969. *Am J Epidemiol.* 1972 Nov;96(5):352-60. PubMed PMID: 4344343.
28. Monto AS, Kendal AP. Effect of neuraminidase antibody on Hong Kong influenza. *Lancet.* 1973 Mar 24;1(7804):623-5. PubMed PMID: 4121842.
29. Monto AS, Brandt BL, Artenstein MS. Response of children to *Neisseria meningitidis* polysaccharide vaccines. *J Infect Dis.* 1973 Apr;127(4):394-400. PubMed PMID: 4632878.
30. Monto AS. The Tecumseh study of respiratory illness V Patterns of infection with the parainfluenzaviruses. *Am J Epidemiol.* 1973 May;97(5):338-48. PubMed PMID: 4349692.
31. Monto AS, Ullman BM. Acute respiratory illness in an American community The Tecumseh study. *JAMA.*

- 1974 Jan 14;227(2):164-9. PubMed PMID: 4357298.
32. Monto AS, Bryan ER. Microneutralization test for detection of rhinovirus antibodies. *Proc Soc Exp Biol Med.* 1974 Feb;145(2):690-4. PubMed PMID: 4360649.
 33. Monto AS, Lim SK. The Tecumseh study of respiratory illness VI Frequency of and relationship between outbreaks of coronavirus infection. *J Infect Dis.* 1974 Mar;129(3):271-6. PubMed PMID: 4816305.
 34. Monto AS. Medical reviews Coronaviruses. *Yale J Biol Med.* 1974 Dec;47(4):234-51. PubMed PMID: 4617423; PubMed Central PMCID: PMC2595130.
 35. Monto AS, Bryan ER, Rhodes LM. The Tecumseh study of respiratory illness VII Further observations on the occurrence of respiratory syncytial virus and Mycoplasma pneumoniae infections. *Am J Epidemiol.* 1974 Dec;100(6):458-68. PubMed PMID: 4374887.
 36. Monto AS, Higgins MW, Ross HW. The Tecumseh study of respiratory illness VIII Acute infection in chronic respiratory disease and comparison groups. *Am Rev Respir Dis.* 1975 Jan;111(1):27-36. PubMed PMID: 163065.
 37. Oberhofer TR, Brown GC, Monto AS. Seroimmunity to poliomyelitis in an American community. *Am J Epidemiol.* 1975 Apr;101(4):333-9. PubMed PMID: 164770.
 38. Monto AS, Kioumehri F. The Tecumseh Study of Respiratory Illness IX Occurrence of influenza in the community, 1966--1971. *Am J Epidemiol.* 1975 Dec;102(6):553-63. PubMed PMID: 1202957.
 39. Monto AS. *Viral Infections of Humans: Epidemiology and Control.* Evans AS, editor. New York: Plenum Medical Book Co.; 1976. Coronaviruses; p.127-41. 584p.
 40. Monto AS, Rhodes LM. Detection of coronavirus infection of man by immunofluorescence. *Proc Soc Exp Biol Med.* 1977 Jun;155(2):143-8. PubMed PMID: 194251.
 41. Monto AS, Maassab HF. Use of influenza vaccine in non-high risk populations. *Dev Biol Stand.* 1977 Jun 1-3;39:329-35. PubMed PMID: 604116.
 42. Monto AS, Ross H. Acute respiratory illness in the community: effect of family composition, smoking, and chronic symptoms. *Br J Prev Soc Med.* 1977 Jun;31(2):101-8. PubMed PMID: 884394; PubMed Central PMCID: PMC479004.
 43. Monto AS, Dickson CB, Landis JR. Utilization and acceptability of influenza A/New Jersey/76 virus vaccine in Oakland County, Michigan. *J Infect Dis.* 1977 Dec;136 Suppl:S693-8. PubMed PMID: 606793.
 44. Monto AS, Ross HW. The Tecumseh study of respiratory illness X Relation of acute infections to smoking, lung function and chronic symptoms. *Am J Epidemiol.* 1978 Jan;107(1):57-64. PubMed PMID: 623090.
 45. Maassab HF, Spring SB, Kendal AP, Monto AS. *Negative Strand Viruses and the Host Cell.* Mahy BW, Barry RD, editors. Massachusetts: Academic Press; 1978. Biologic characteristics of influenza virus recombinants derived at suboptimal temperature; p.721-32.
 46. Austin MA, Monto AS, Maassab HF. Growth characteristics of influenza virus type C in avian hosts Brief report. *Arch Virol.* 1978;58(4):349-53. PubMed PMID: 736797.
 47. Monto AS, Bryan ER. Susceptibility to rhinovirus infection in chronic bronchitis. *Am Rev Respir Dis.* 1978 Dec;118(6):1101-3. PubMed PMID: 217286.
 48. Monto AS, Ross HW. Swine influenza vaccine program in the community: acceptability, reactions and responses. *Am J Public Health.* 1979 Mar;69(3):233-7. PubMed PMID: 217281; PubMed Central PMCID: PMC1619086.
 49. Monto AS, Gunn RA, Bandyk MG, King CL. Prevention of Russian influenza by amantadine. *JAMA.* 1979 Mar 9;241(10):1003-7. PubMed PMID: 368354.

50. Monto AS, Maassab HF. Effect of cyclic nucleotide on coronavirus replication. *Proc Soc Exp Biol Med.* 1979 Jun;161(2):183-5. PubMed PMID: 221932.
51. Fannin KF, Cochran KW, Lamphiear DE, Monto AS. Acute Illness Differences with Regard to Distance from the Tecumseh, Michigan, Wastewater Treatment Plant in Wastewater Aerosols and Diseases, Proceedings of a Symposium September 1979. Pahren HA, Jakubowski W, editors. Cincinnati, Ohio: U.S. Environmental Protection Agency, EPA #600980028; 1980. p.117-135.
52. Monto AS. Maxcy-Rosenau Public Health and Preventive Medicine. 11th ed. Last J, editor. New York: Appleton-Century-Crofts; 1980. Acute respiratory disease; Viral infections of the gastrointestinal tract; p.121-31; 131-5.
53. Monto AS, Koopman JS. The Tecumseh Study XI Occurrence of acute enteric illness in the community. *Am J Epidemiol.* 1980 Sep;112(3):323-33. PubMed PMID: 7424881.
54. Luscombe FA, Monto AS, Baublis JV. Mortality due to Reye's syndrome in Michigan: distribution and longitudinal trends. *J Infect Dis.* 1980 Sep;142(3):363-71. PubMed PMID: 7441007.
55. Monto AS, Maassab HF, Bryan ER. Relative efficacy of embryonated eggs and cell culture for isolation of contemporary influenza viruses. *J Clin Microbiol.* 1981 Jan;13(1):233-5. PubMed PMID: 7462417; PubMed Central PMCID: PMC273760.
56. Monto AS, Maassab HF. Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test. *J Clin Microbiol.* 1981 Jan;13(1):54-7. PubMed PMID: 7462419; PubMed Central PMCID: PMC273720.
57. Maassab HF, Monto AS, DeBorde DC, Cox NJ, Kendal SP. ICN-UCLA Symposia on Molecular and Cellular Biology - Genetic Variation among Influenza Viruses. Nayak DP, editor. New York: Academic Press; 1981. Development of cold recombinants of influenza virus as live virus vaccines; p.617-37.
58. Maassab HF, Smitka CW, Donabedian AM, Monto AS, Cox NJ, Kendal AP. The Replication of Negative Strand Viruses. Bishop DH, Compans RS, editors. New York: Elsevier - North Holland, Inc; 1981. Characteristics of influenza virus "cold" recombinants derived at the non-permissive temperature (38°); p.395-404.
59. Monto AS, Maassab HF. Serologic responses to nonprevalent influenza A viruses during intercytic periods. *Am J Epidemiol.* 1981 Mar;113(3):236-44. PubMed PMID: 7193408.
60. Monto AS, Ceglarek JP, Hayner NS. Liver function abnormalities in the course of a type A (H1N1) influenza outbreak: relation to Reye's syndrome. *Am J Epidemiol.* 1981 Nov;114(5):750-9. PubMed PMID: 7304602.
61. Troisi CL, Monto AS. Comparison of enzyme-linked immunosorbent assay and hemagglutination inhibition in a seroepidemiological study of influenza type C infection. *J Clin Microbiol.* 1981 Nov;14(5):516-21. PubMed PMID: 7309849; PubMed Central PMCID: PMC273979.
62. Miller F, Hussein M, Mancy KH, Hilbert MS, Monto AS, Barakat RM. An epidemiological study of *Schistosoma haematobium* and *S mansoni* infection in thirty-five rural Egyptian villages. *Trop Geogr Med.* 1981 Dec;33(4):355-65. PubMed PMID: 7342382.
63. Monto AS, Miller FD, Maassab HF. Evaluation of an attenuated, cold-recombinant influenza B virus vaccine. *J Infect Dis.* 1982 Jan;145(1):57-64. PubMed PMID: 7054318.
64. Monto AS. *Viral Infections of Humans: epidemiology and control* . 2nd ed. Evans AS, editor. New York: Plenum Medical Book Publishing Company; 1982. Coronaviruses; p.151-65.
65. Monto AS. Book Review: *Pure Politics and Impure Science: The Swine Flu Affair.* *JAMA.* 1982; 247:3268-69.

66. Koopman JS, Eckert EA, Greenberg HB, Strohm BC, Isaacson RE, Monto AS. Norwalk virus enteric illness acquired by swimming exposure. *Am J Epidemiol.* 1982 Feb;115(2):173-7. PubMed PMID: 6277185.
67. King CL, Miller FD, Hussein M, Barkat R, Monto AS. Prevalence and intensity of *Schistosoma haematobium* infection in six villages of upper Egypt. *Am J Trop Med Hyg.* 1982 Mar;31(2):320-7. PubMed PMID: 7072897.
68. Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. *Am J Epidemiol.* 1982 May;115(5):736-51. PubMed PMID: 7081204.
69. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. *J Infect Dis.* 1982 Dec;146(6):780-90. PubMed PMID: 7142749.
70. Monto AS. Coordination of epidemiologic studies of respiratory infection. *Ped Res.* 1983;17:1062-4.
71. Longini IM Jr, Koopman JS, Monto AS. [Procedures for estimating transmission parameters from influenza epidemics: use of serological data]. *Vopr Virusol.* 1983 Mar-Apr;PubMed PMID: 6868556.
72. Wright PF, Cherry JD, Foy HM, Glezen WP, Hall CB, McIntosh K, Monto AS, Parrott RH, Portnoy B, Tabor LH. Antigenicity and reactogenicity of influenza A/USSR/77 virus vaccine in children--a multicentered evaluation of dosage and safety. *Rev Infect Dis.* 1983 Jul-Aug;5(4):758-64. PubMed PMID: 6353530.
73. Monto AS, Koopman JS, Longini IM, Isaacson RE. The Tecumseh study XII Enteric agents in the community, 1976-1981. *J Infect Dis.* 1983 Aug;148(2):284-91. PubMed PMID: 6310002.
74. Monto AS. Prevention and drug treatment of influenza. *Am Fam Physician.* 1983 Dec;28(6):165-9. PubMed PMID: 6650333.
75. Koopman JS, Turkish VJ, Monto AS, Gouvea V, Srivastava S, Isaacson RE. Patterns and etiology of diarrhea in three clinical settings. *Am J Epidemiol.* 1984 Jan;119(1):114-23. PubMed PMID: 6691328.
76. Higashi GI, Isaacson RE, Monto AS. Textbook of Public Health. Holland W, editor. New York: Oxford University Press; 1984. Determinants of health and disease: Infectious agents; p.77-96.
77. Monto AS. Rimantadine prophylaxis of influenza A. *Microbiology.* 1984; :424-6.
78. Longini IM Jr, Monto AS, Koopman JS. Statistical procedures for estimating the community probability of illness in family studies: rhinovirus and influenza. *Int J Epidemiol.* 1984 Mar;13(1):99-106. PubMed PMID: 6321368.
79. Monto AS. Epidemiologic designs for the study of acquired immunodeficiency disease: options and obstacles. *Rev Infect Dis.* 1984 Sep-Oct;6(5):720-5. PubMed PMID: 6505498.
80. Koopman JS, Turkish VJ, Monto AS, Thompson FE, Isaacson RE. Milk fat and gastrointestinal illness. *Am J Public Health.* 1984 Dec;74(12):1371-3. PubMed PMID: 6095691; PubMed Central PMCID: PMC1652700.
81. Longini IM Jr, Seaholm SK, Ackerman E, Koopman JS, Monto AS. Simulation studies of influenza epidemics: assessment of parameter estimation and sensitivity. *Int J Epidemiol.* 1984 Dec;13(4):496-501. PubMed PMID: 6519891.
82. Miller FD, Monto AS, DeLong DC, Exelby A, Bryan ER, Srivastava S. Controlled trial of enviroxime against natural rhinovirus infections in a community. *Antimicrob Agents Chemother.* 1985 Jan;27(1):102-6. PubMed PMID: 2984980; PubMed Central PMCID: PMC176213.
83. Monto AS. Laboratory diagnosis of viral infections. Lennette EH, editor. New York: Marcel Dekker, Inc; 1985. Coronaviruses; p.213-24.
84. Monto AS. Acute Respiratory Infections in Childhood. Douglas RM, Kerby-Eaton E, editors. Australia:

- University of Adelaide Press; 1985. Aetiology of acute respiratory infections in the United States; p.45-7.
85. Monto AS. Laboratory Diagnosis of Viral Infections. Lennette EH, editor. New York: Marcel Dekker, Inc; 1985. Parainfluenza viruses; p.385-99.
 86. Monto AS. Acute Respiratory Infections in Childhood. Douglas RM, Kerby-Eaton E, editors. Australia: University of Adelaide Press; 1985. Prospects for control of rhinovirus and coronavirus infections; p.62-6.
 87. Koopman JS, Turkish VJ, Monto AS. Infant formulas and gastrointestinal illness. *Am J Public Health*. 1985 May;75(5):477-80. PubMed PMID: 2984949; PubMed Central PMCID: PMC1646279.
 88. Monto AS, Koopman JS, Longini IM Jr. Tecumseh study of illness XIII Influenza infection and disease, 1976-1981. *Am J Epidemiol*. 1985 Jun;121(6):811-22. PubMed PMID: 4014174.
 89. Remington PL, Rowley D, McGee H, Hall WN, Monto AS. Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984. *Pediatrics*. 1986 Jan;77(1):93-8. PubMed PMID: 3940363.
 90. Hayden FG, Monto AS. Oral rimantadine hydrochloride therapy of influenza A virus H3N2 subtype infection in adults. *Antimicrob Agents Chemother*. 1986 Feb;29(2):339-41. PubMed PMID: 3521480; PubMed Central PMCID: PMC176405.
 91. Monto AS, Shope TC, Schwartz SA, Albrecht JK. Intranasal interferon-alpha 2b for seasonal prophylaxis of respiratory infection. *J Infect Dis*. 1986 Jul;154(1):128-33. PubMed PMID: 3011917.
 92. Monto AS, Koopman JS, Bryan ER. The Tecumseh Study of Illness XIV Occurrence of respiratory viruses, 1976-1981. *Am J Epidemiol*. 1986 Sep;124(3):359-67. PubMed PMID: 3017099.
 93. Schwartz SA, Monto AS. Prophylaxis of acute viral upper respiratory infections with intranasal interferon. *Infect Med*. 1987;
 94. Monto AS. Influenza: quantifying morbidity and mortality. *Am J Med*. 1987 Jun 19;82(6A):20-5. PubMed PMID: 3591814.
 95. Monto AS, Bryan ER, Ohmit S. Rhinovirus infections in Tecumseh, Michigan: frequency of illness and number of serotypes. *J Infect Dis*. 1987 Jul;156(1):43-9. PubMed PMID: 3036962.
 96. Hamparian VV, Colonno RJ, Cooney MK, Dick EC, Gwaltney JM Jr, Hughes JH, Jordan WS, Kapikian AZ, Mogabgab WJ, Monto AS, Phillips CA (in absentia), Rueckert RR, Schieble JH, Stott EJ, DAI Tyrell (in absentia). A collaborative report: rhinoviruses--extension of the numbering system from 89 to 100. *Virology*. 1987 Jul;159(1):191-2. PubMed PMID: 3037780.
 97. Monto AS, Albrecht JK, Schwartz SA. Demonstration of dose-response relationship in seasonal prophylaxis of respiratory infections with alpha-2b interferon. *Antimicrob Agents Chemother*. 1988 Jan;32(1):47-50. PubMed PMID: 2831814; PubMed Central PMCID: PMC172096.
 98. Longini IM Jr, Monto AS. Efficacy of virucidal nasal tissues in interrupting familial transmission of respiratory agents A field trial in Tecumseh, Michigan. *Am J Epidemiol*. 1988 Sep;128(3):639-44. PubMed PMID: 2843040.
 99. Betts RF, Hayden FG, Monto AS. Safety and tolerance of a loading dose of rimantadine. *J Resp Dis*. 1989; :S42-5.
 100. Monto AS. *Viral Infections of Humans*. 3rd ed. Evans AS, editor. New York: Plenum Publishing Company; 1989. Coronaviruses; p.153-67.
 101. Monto AS. New Vaccines: Introduction, Part 2. *Reviews of Infectious Diseases* . 1989; 11 :S586-S587.
 102. Monto AS, Schwartz SA, Albrecht JK. Ineffectiveness of postexposure prophylaxis of rhinovirus infection with low-dose intranasal alpha 2b interferon in families. *Antimicrob Agents Chemother*. 1989 Mar;33(3):387-90. PubMed PMID: 2543280; PubMed Central PMCID: PMC171498.

103. Monto AS. Acute respiratory infection in children of developing countries: challenge of the 1990s. *Rev Infect Dis.* 1989 May-Jun;11(3):498-505. PubMed PMID: 2665005.
104. Koopman JS, Monto AS. The Tecumseh Study XV: Rotavirus infection and pathogenicity. *Am J Epidemiol.* 1989 Oct;130(4):750-9. PubMed PMID: 2549788.
105. Koopman JS, Monto AS, Longini IM Jr. The Tecumseh Study XVI: Family and community sources of rotavirus infection. *Am J Epidemiol.* 1989 Oct;130(4):760-8. PubMed PMID: 2773919.
106. Monto AS. *Conn's Current Therapy.* Rakel RE, editor. Philadelphia: WB Saunders; 1990. Influenza 1184p.
107. Sullivan KM, Monto AS, Foster DA. Antibody response to inactivated influenza vaccines of various antigenic concentrations. *J Infect Dis.* 1990 Feb;161(2):333-5. PubMed PMID: 2299213.
108. Monto AS, Ohmit S. Respiratory syncytial virus in a community population: circulation of subgroups A and B since 1965. *J Infect Dis.* 1990 Apr;161(4):781-3. PubMed PMID: 2319169.
109. Monto AS, Higashi GI, Marrs CF. *Textbook of Public Health.* New York: Oxford University Press; 1991. Determinants of disease: The infectious process
110. Monto AS. Book Review: *History, Epidemiology: Expectations of life: Study in the demography, statistics, and history of world mortality,* by H.O. Lancaster. *JAMA.* 1991 January 09; 265(2):283.
111. Abdeljaber MH, Monto AS, Tilden RL, Schork MA, Tarwotjo I. The impact of vitamin A supplementation on morbidity: a randomized community intervention trial. *Am J Public Health.* 1991 Dec;81(12):1654-6. PubMed PMID: 1746667; PubMed Central PMCID: PMC1405285.
112. Monto AS. *Maxcy-Rosenau-Last Public Health and Preventive Medicine.* 13th ed. Last JM, Wallace RB, editors. Norwalk, Connecticut: Appleton & Lange; 1992. Acute respiratory infections; p.125-30; 145-7. 1257p.
113. Monto AS, Shaw MW. *Laboratory Diagnosis of Viral Infections.* 2nd ed. Lennette EH, editor. New York: Marcel Dekker, Inc; 1992. Coronaviruses; p.319-32.
114. Monto AS, Shaw MW. *Laboratory Diagnosis of Viral Infections.* 2nd ed. Lennette EH, editor. New York: Marcel Dekker, Inc; 1992. Parainfluenza viruses; p.573-89.
115. Rampey AH Jr, Longini IM Jr, Haber M, Monto AS. A discrete-time model for the statistical analysis of infectious disease incidence data. *Biometrics.* 1992 Mar;48(1):117-28. PubMed PMID: 1316178.
116. Foster DA, Talsma A, Furumoto-Dawson A, Ohmit SE, Margulies JR, Arden NH, Monto AS. Influenza vaccine effectiveness in preventing hospitalization for pneumonia in the elderly. *Am J Epidemiol.* 1992 Aug 1;136(3):296-307. PubMed PMID: 1415151.
117. Monto AS, Arden NH. Implications of viral resistance to amantadine in control of influenza A. *Clin Infect Dis.* 1992 Aug;15(2):362-7; discussion 368-9. PubMed PMID: 1520770.
118. Abdeljaber MH, Monto AS, Tilden RL, Schork A. Response Letter: Abdeljaber and Colleagues Respond. *American Journal of Public Health.* 1993; 83:289.
119. Monto AS. *Maxcy-Rosenau-Last Public Health and Preventive Medicine.* 14th ed. Wallace RB, editor. Stamford, Connecticut: Appleton & Lange; 1993. Acute respiratory infections; p.169-74. 1291p.
120. Arden N, Bidol S, Ohmit S, Monto AS. Options for the Control of Influenza II. Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Amsterdam: Elsevier Science Publishers B.V.; 1993. Effect of nursing home size and influenza vaccination rates on the risk of institutional outbreaks during an influenza A (H3N2) epidemic; p.161-5.
121. Monto AS, Ohmit SE, Foster DA, Furumoto-Dawson A, Arden NA. Options for the Control of Influenza II. Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Amsterdam: Elsevier Science Publishers B.V.; 1993. Case-control study in Michigan on prevention of hospitalization by vaccination, 1989-1991;

p.135-41.

122. Rudenko LG, Slepushkin AN, Kendal AP, Beljaev AL, Burtseva EI, Ivanova VT, Petrov LI, Ghendon YZ, Alexandrova GI, Cox NJ. Options for the Control of Influenza II. Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Amsterdam: Elsevier Science Publishers B.V.; 1993. Comparative studies of live and inactivated vaccines in Novgorod: Description of study design and results of reactogenicity and immunogenicity of vaccines; p.91-6.
123. Rudenko LG, Slepushkin AN, Monto AS, Grigorieva EP, Rekstin AR, Brangina VE, Kendal AP, Cox NJ, Gendon YZ, Alexandrova GI. Options for the Control of Influenza II. Hannoun C, Kendal AP, Klenk HD, Ruben FL, editors. Amsterdam: Elsevier Science Publishers B.V.; 1993. Comparative studies of the efficacy of live attenuated and inactivated vaccines in children in Novgorod; p.85-90.
124. Monto AS, Sullivan KM. Acute respiratory illness in the community Frequency of illness and the agents involved. *Epidemiol Infect.* 1993 Feb;110(1):145-60. PubMed PMID: 8432318; PubMed Central PMCID: PMC2271959.
125. Rudenko LG, Slepushkin AN, Monto AS, Kendal AP, Grigorieva EP, Burtseva EP, Rekstin AR, Beljaev AL, Bragina VE, Cox N, Ghendon YZ, Alexandrova GI. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. *J Infect Dis.* 1993 Oct;168(4):881-7. PubMed PMID: 8376833.
126. Sullivan KM, Monto AS, Longini IM Jr. Estimates of the US health impact of influenza. *Am J Public Health.* 1993 Dec;83(12):1712-6. PubMed PMID: 8259800; PubMed Central PMCID: PMC1694912.
127. Monto AS. Studies of the community and family: acute respiratory illness and infection. *Epidemiol Rev.* 1994;16(2):351-73. PubMed PMID: 7713184.
128. Monto AS. The common cold: Cold water on hot news. *JAMA.* 1994 Apr 13;271(14):1122-4. PubMed PMID: 8151858.
129. Slepushkin AN, Rudenko LG, Kendal AP, Monto AS, Beliaev AL, Burtseva EI, Grigor'eva EP, Obrosova-Serova NP, Ivanova VT, Bragina VE et al. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity]. *Vopr Virusol.* 1994 May-Jun;39(3):129-31. PubMed PMID: 8091754.
130. Monto AS. Influenza vaccines for the elderly. *N Engl J Med.* 1994 Sep 22;331(12):807-8. PubMed PMID: 8065412.
131. Monto AS. Using antiviral agents to control outbreaks of influenza A infection. *Geriatrics.* 1994 Dec;49(12):30-4. PubMed PMID: 7982583.
132. Arden N, Monto AS, Ohmit SE. Vaccine use and the risk of outbreaks in a sample of nursing homes during an influenza epidemic. *Am J Public Health.* 1995 Mar;85(3):399-401. PubMed PMID: 7892927; PubMed Central PMCID: PMC1614859.
133. Monto AS, Ohmit SE, Margulies JR, Talsma A. Medical practice-based influenza surveillance: viral prevalence and assessment of morbidity. *Am J Epidemiol.* 1995 Mar 15;141(6):502-6. PubMed PMID: 7900716.
134. Monto AS. Epidemiology of respiratory viruses in persons with and without asthma and COPD. *Am J Respir Crit Care Med.* 1995 May;151(5):1653-7; discussion 1657-8. PubMed PMID: 7735629.
135. Ohmit SE, Furumoto-Dawson A, Monto AS, Fasano N. Influenza vaccine use among an elderly population in a community intervention. *Am J Prev Med.* 1995 Jul-Aug;11(4):271-6. PubMed PMID: 7495605.
136. Monto AS, Ohmit SE, Hornbuckle K, Pearce CL. Safety and efficacy of long-term use of rimantadine for

- prophylaxis of type A influenza in nursing homes. *Antimicrob Agents Chemother.* 1995 Oct;39(10):2224-8. PubMed PMID: 8619572; PubMed Central PMCID: PMC162919.
137. Ohmit SE, Monto AS. Influenza vaccine effectiveness in preventing hospitalization among the elderly during influenza type A and type B seasons. *Int J Epidemiol.* 1995 Dec;24(6):1240-8. PubMed PMID: 8824869.
 138. Monto AS. Viral respiratory infections in the community: epidemiology, agents, and interventions. *Am J Med.* 1995 Dec 29;99(6B):24S-27S. PubMed PMID: 8585553.
 139. Monto AS. The clinical efficacy of influenza vaccination. *Pharmacoeconomics.* 1996;9 Suppl 3:16-22; discussion 23-5. PubMed PMID: 10160482.
 140. Monto AS. Viral respiratory tract infections in the immunocompetent. *Current Opinion in Infectious Diseases .* 1996; 9:85-88.
 141. Monto AS, Ohmit SE. Options for the Control of Influenza III. Brown LE, editor. Amsterdam: Elsevier Science BV; 1996. Effectiveness evaluation of inactivated influenza vaccines: methods and results; p.93-6.
 142. Monto AS. Options for the Control of Influenza III. Brown LE, editor. Amsterdam: Elsevier Science BV; 1996. The evolving epidemiology of influenza infection and disease; p.45-9.
 143. Monto AS. *Medicine.* Vol 24:9. Levers AM, Sissons P, editors. Abingdon, UK: The Medicine Group (Journals) Ltd; 1996. Infections: Influenza; p.100.
 144. Monto AS, Terpenning MS. The value of influenza and pneumococcal vaccines in the elderly. *Drugs Aging.* 1996 Jun;8(6):445-51. PubMed PMID: 8736628.
 145. Ohmit SE, Moler FW, Monto AS, Khan AS. Ribavirin utilization and clinical effectiveness in children hospitalized with respiratory syncytial virus infection. *J Clin Epidemiol.* 1996 Sep;49(9):963-7. PubMed PMID: 8780603.
 146. Monto AS, Iacuzio DA, La Montagne JR. Pandemic Influenza—Confronting a Reemergent Threat. *The Journal of Infectious Diseases.* 1997; 176(Suppl 1):S1-3.
 147. Monto AS, Marris C. *Oxford Textbook of Public Health.* Third ed. Oxford, England: Oxford University Press; 1997. Determinants of health and disease: Infectious agents; p.175-98.
 148. Monto AS. Prospects for pandemic influenza control with currently available vaccines and antivirals. *J Infect Dis.* 1997 Aug;176 Suppl 1:S32-7. PubMed PMID: 9240692.
 149. Monto AS. *Textbook of Influenza.* Nicholson KG, Webster RG, Hay AJ, editors. London: Blackwell Science Ltd.; 1998. Chapter 38, Guidelines for the clinical use of antivirals; p.506-14. 578p.
 150. Monto AS. *Topley & Wilson's Microbiology and Microbial Infections.* Ninth ed. London: Arnold; 1998. Viral epidemiology; p.235.
 151. Monto AS, Lehmann D. Acute respiratory infections (ARI) in children: prospects for prevention. *Vaccine.* 1998 Oct;16(16):1582-8. PubMed PMID: 9711807.
 152. Monto AS. Francis field trial of inactivated poliomyelitis vaccine: background and lessons for today. *Epidemiol Rev.* 1999;21(1):7-23. PubMed PMID: 10520470.
 153. Monto A. *Managing Influenza in Primary Care.* 1st ed. Nicholson KG, editor. Oxford, England: Wiley-Blackwell; 1999. Foreword; p.xi-xii.
 154. Monto AS. Individual and community impact of influenza. *Pharmacoeconomics.* 1999;16 Suppl 1:1-6. PubMed PMID: 10623371.
 155. Monto AS. *Advances in Influenza.* International Medical Forum 104. Zambon MC, editor. Madrid, Spain. Oxford, Great Britain: Blackwell Science Ltd; 1999. The role of antivirals in prophylaxis; p.39-44.

156. Monto AS. *Viral Infections of the Respiratory Tract*. Dolan R, Wright PF, editors. New York: Marcel Dekker, Inc; 1999. Therapy of viral respiratory infections; p.327-53.
157. Monto AS. *Current Treatment Options*. PA: Current Science Inc; 1999. The prevention and treatment of influenza
158. Monto AS, Marris C. *Oxford Textbook of Public Health*. Third ed. New York and London: Oxford University Press; 1999. Determinants of health and disease: Infectious agents
159. Ohmit SE, Arden NH, Monto AS. Effectiveness of inactivated influenza vaccine among nursing home residents during an influenza type A (H3N2) epidemic. *J Am Geriatr Soc*. 1999 Feb;47(2):165-71. PubMed PMID: 9988287.
160. Monto AS. Interrupting the transmission of respiratory tract infections: theory and practice. *Clin Infect Dis*. 1999 Feb;28(2):200-4. PubMed PMID: 10064226.
161. Monto AS. The disappearance of Reye's syndrome--a public health triumph. *N Engl J Med*. 1999 May 6;340(18):1423-4. PubMed PMID: 10228195.
162. Monto AS, Robinson DP, Herlocher ML, Hinson JM Jr, Elliott MJ, Crisp A. Zanamivir in the prevention of influenza among healthy adults: a randomized controlled trial. *JAMA*. 1999 Jul 7;282(1):31-5. PubMed PMID: 10404908.
163. Monto AS, Victor JC. Hepatitis A vaccine for secondary hepatitis A infection. *Lancet*. 1999 Jul 24;354(9175):341-2; author reply 342-3. PubMed PMID: 10440344.
164. Monto AS, Fleming DM, Henry D, de Groot R, Makela M, Klein T, Elliott M, Keene ON, Man CY. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenza A and B virus infections. *J Infect Dis*. 1999 Aug;180(2):254-61. PubMed PMID: 10395837.
165. Monto AS, Gravenstein S, Elliot M, Colopy M, Cobb M, Freund B. Clinical predictors of an acute influenza epidemic with laboratory confirmation. 39th Interscience Conference of Antimicrobial Agents and Chemotherapy; 1999 September 26; San Francisco, Calif, US.
166. Monto AS, Webster A, Keene O. Randomized, placebo-controlled studies of inhaled zanamivir in the treatment of influenza A and B: pooled efficacy analysis. *J Antimicrob Chemother*. 1999 Nov;44 Suppl B:23-9. PubMed PMID: 10877459.
167. Cram P, Blitz SG, Monto A, Fendrick AM. Diagnostic testing for influenza: review of current status and implications of newer treatment options. *Am J Manag Care*. 1999 Dec;5(12):1555-61; quiz 1562-3. PubMed PMID: 11066622.
168. Monto AS. Epidemiology and virology of influenza illness. *The American journal of managed care*. 2000; 6(Suppl):S255.
169. Monto AS, Fendrick AM. Developments in influenza prevention and treatment: A managed care perspective. *Dis Manage Health Outcomes*. 2000; 7(5):235.
170. Monto AS. Acute respiratory infections in childhood: Prospects for vaccine prevention. *Annales Nestle*. 2000; 58:66-73.
171. McElroy PD, ter Kuile FO, Lal AA, Bloland PB, Hawley WA, Oloo AJ, Monto AS, Meshnick SR, Nahlen BL. Effect of Plasmodium falciparum parasitemia density on hemoglobin concentrations among full-term, normal birth weight children in western Kenya, IV The Asembo Bay Cohort Project. *Am J Trop Med Hyg*. 2000 Apr;62(4):504-12. PubMed PMID: 11220768.
172. Monto AS. Preventing influenza in healthy adults: the evolving story. *JAMA*. 2000 Oct 4;284(13):1699-701. PubMed PMID: 11015802.
173. Monto AS, Moulton AB, Sharp SJ. Effect of zanamivir on duration and resolution of influenza symptoms.

- Clin Ther. 2000 Nov;22(11):1294-305. PubMed PMID: 11117654.
174. Hayden FG, Gubareva LV, Monto AS, Klein TC, Elliot MJ, Hammond JM, Sharp SJ, Ossi MJ. Inhaled zanamivir for the prevention of influenza in families Zanamivir Family Study Group. N Engl J Med. 2000 Nov 2;343(18):1282-9. PubMed PMID: 11058672.
 175. Monto AS, Gravenstein S, Elliott M, Colopy M, Schweinle J. Clinical signs and symptoms predicting influenza infection. Arch Intern Med. 2000 Nov 27;160(21):3243-7. PubMed PMID: 11088084.
 176. Monto AS. Updating the Approach to Influenza. Hospital Practice. 2000 December; 35(12).
 177. Cram P, Blitz SG, Monto AS, Fendrick AM. Influenza: Cost of illness and considerations in the economic evaluation of new and emerging therapies. Pharmaco Economics. 2001; 19:223-30.
 178. Welliver R, Monto AS, Carewicz O, Schatteman E, Hassman M, Hedrick J, Jackson HC, Huson L, Ward P, Oxford. Effectiveness of oseltamivir in preventing influenza in household contacts: a randomized controlled trial. JAMA. 2001 Feb 14;285(6):748-54. PubMed PMID: 11176912.
 179. Monto AS, Hornbuckle K, Ohmit SE. Influenza vaccine effectiveness among elderly nursing home residents: a cohort study. Am J Epidemiol. 2001 Jul 15;154(2):155-60. PubMed PMID: 11447049.
 180. Herlocher ML, Elias S, Truscon R, Harrison S, Mindell D, Simon C, Monto AS. Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J Infect Dis. 2001 Sep 1;184(5):542-6. PubMed PMID: 11494159.
 181. Monto AS, Fendrick AM, Sarnes MW. Respiratory illness caused by picornavirus infection: a review of clinical outcomes. Clin Ther. 2001 Oct;23(10):1615-27. PubMed PMID: 11726001.
 182. Monto AS. Contemporary Diagnosis, Prevention, and Management of Influenza. First ed. Newton, Pennsylvania: Handbooks in Health Care Co.; 2002. 127p.
 183. Blitz SG, Cram P, Chernew ME, Monto AS, Fendrick AM. Diagnostic testing or empirical neuraminidase inhibitor therapy for patients with influenza-like illness: what a difference a day makes. Am J Manag Care. 2002 Mar;8(3):221-7. PubMed PMID: 11915972.
 184. Monto AS. Epidemiology of viral respiratory infections. Am J Med. 2002 Apr 22;112 Suppl 6A:4S-12S. PubMed PMID: 11955454.
 185. Herlocher ML, Carr J, Ives J, Elias S, Truscon R, Roberts N, Monto AS. Influenza virus carrying an R292K mutation in the neuraminidase gene is not transmitted in ferrets. Antiviral Res. 2002 May;54(2):99-111. PubMed PMID: 12062395.
 186. Monto AS. American vaccine recommendations: Rational and effectiveness considerations. 2nd. National Symposium of Advances in Vaccines, Barcelona, Spain. 2002 October.
 187. Monto AS, Pichichero ME, Blanckenberg SJ, Ruuskanen O, Cooper C, Fleming DM, Kerr C. Zanamivir prophylaxis: an effective strategy for the prevention of influenza types A and B within households. J Infect Dis. 2002 Dec 1;186(11):1582-8. PubMed PMID: 12447733.
 188. Monto AS. The seasonality of rhinovirus infections and its implications for clinical recognition. Clin Ther. 2002 Dec;24(12):1987-97. PubMed PMID: 12581541.
 189. Loughlin J, Poullos N, Napalkov P, Wegmüller Y, Monto AS. A study of influenza and influenza-related complications among children in a large US health insurance plan database. Pharmacoeconomics. 2003;21(4):273-83. PubMed PMID: 12600222.
 190. Monto AS. SARS. Chicago, IL: World Book Publishing; 2003.
 191. Monto AS, Bramley TJ, Sarnes M. Development of a predictive index for picornavirus infections. Clin Infect Dis. 2003 Feb 1;36(3):253-8. PubMed PMID: 12539064.
 192. Fendrick AM, Monto AS, Nightengale B, Sarnes M. The economic burden of non-influenza-related viral

- respiratory tract infection in the United States. *Arch Intern Med*. 2003 Feb 24;163(4):487-94. PubMed PMID: 12588210.
193. Monto AS. The role of antivirals in the control of influenza. *Vaccine*. 2003 May 1;21(16):1796-800. PubMed PMID: 12686097.
194. Monto AS. Invited commentary: Use of selective viral cultures to adjust nonvirologic endpoints in studies of influenza vaccine efficacy. *Am J Epidemiol*. 2003 Aug 15;158(4):312-5. PubMed PMID: 12915496.
195. Monto AS. Book Review: The global threat of new and reemerging infectious diseases: Reconciling U.S. national security and public health policy. *Am J Epidemiol*. 2003 September 15; 158(6):606.
196. Herlocher ML, Truscon R, Fenton R, Klimov A, Elias S, Ohmit SE, Monto AS. Assessment of development of resistance to antivirals in the ferret model of influenza virus infection. *J Infect Dis*. 2003 Nov 1;188(9):1355-61. PubMed PMID: 14593594.
197. Monto AS. Occurrence of respiratory virus: time, place and person. *Pediatr Infect Dis J*. 2004 Jan;23(1 Suppl):S58-64. PubMed PMID: 14730271.
198. Monto AS. Options for the Control of Influenza V. Okinawa, Japan: Elsevier, International Congress Series; 2004. Global burden of influenza: What we know and what we need to know; p.3-11.
199. Sperber SJ, Shah LP, Gilbert RD, Ritchey TW, Monto AS. Echinacea purpurea for prevention of experimental rhinovirus colds. *Clin Infect Dis*. 2004 May 15;38(10):1367-71. PubMed PMID: 15156472.
200. Monto AS, Rotthoff J, Teich E, Herlocher ML, Truscon R, Yen HL, Elias S, Ohmit SE. Detection and control of influenza outbreaks in well-vaccinated nursing home populations. *Clin Infect Dis*. 2004 Aug 15;39(4):459-64. PubMed PMID: 15356805.
201. Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS. Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets. *J Infect Dis*. 2004 Nov 1;190(9):1627-30. PubMed PMID: 15478068.
202. Fleming DM, Monto AS. Correspondence: Influenza Vaccination in Children with Asthma: No reason to change current recommendations. *American Journal of Respiratory and Critical Care Medicine*. 2005; 171(8):931.
203. Hayden F, Klimov A, Tashiro M, Hay A, Monto A, McKimm-Breschkin J, Macken C, Hampson A, Webster RG, Amyard M, Zambon M. Neuraminidase inhibitor susceptibility network position statement: antiviral resistance in influenza A/H5N1 viruses. *Antivir Ther*. 2005;10(8):873-7. PubMed PMID: 16430192.
204. Monto AS. Topley and Wilson's Microbiology and Microbial Infections: Virology Vol. 1. Tenth ed. Mahy BW, Ter Meulen V, editors. London: Hodder Arnold; 2005. The epidemiology of viral infections; p.353-77.
205. Monto AS. The threat of an avian influenza pandemic. *N Engl J Med*. 2005 Jan 27;352(4):323-5. PubMed PMID: 15668220.
206. Englund JA, Walter EB, Fairchok MP, Monto AS, Neuzil KM. A comparison of 2 influenza vaccine schedules in 6- to 23-month-old children. *Pediatrics*. 2005 Apr;115(4):1039-47. PubMed PMID: 15805382.
207. Yen HL, Monto AS, Webster RG, Govorkova EA. Virulence may determine the necessary duration and dosage of oseltamivir treatment for highly pathogenic A/Vietnam/1203/04 influenza virus in mice. *J Infect Dis*. 2005 Aug 15;192(4):665-72. PubMed PMID: 16028136.
208. Yen HL, Herlocher LM, Hoffmann E, Matrosovich MN, Monto AS, Webster RG, Govorkova EA. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and

- transmissibility. *Antimicrob Agents Chemother.* 2005 Oct;49(10):4075-84. PubMed PMID: 16189083; PubMed Central PMCID: PMC1251536.
209. Cinti S, Chenoweth C, Monto AS. Preparing for pandemic influenza: should hospitals stockpile oseltamivir?. *Infect Control Hosp Epidemiol.* 2005 Nov;26(11):852-4. PubMed PMID: 16320980.
210. Monto AS. Vaccines and antiviral drugs in pandemic preparedness. *Emerg Infect Dis.* 2006 Jan;12(1):55-60. PubMed PMID: 16494718; PubMed Central PMCID: PMC3291404.
211. World Health Organization Writing Group: Bell D, Nicoll A, Fukuda K, Horby P, Monto A, Hayden F, Wylks C, Sanders L, van Tam J. Non-pharmaceutical interventions for pandemic influenza, national and community measures. *Emerg Infect Dis.* 2006 Jan;12(1):88-94. PubMed PMID: 16494723; PubMed Central PMCID: PMC3291415.
212. World Health Organization Writing Group: Bell D, Nicoll A, Fukuda K, Horby P, Monto A, Hayden F, Wylks C, Sanders L, van Tam J. Non-pharmaceutical interventions for pandemic influenza, international measures. *Emerg Infect Dis.* 2006 Jan;12(1):81-7. PubMed PMID: 16494722; PubMed Central PMCID: PMC3291414.
213. Victor JC, Surdina TY, Suleimenova SZ, Favorov MO, Bell BP, Monto AS. Person-to-person transmission of hepatitis A virus in an urban area of intermediate endemicity: implications for vaccination strategies. *Am J Epidemiol.* 2006 Feb 1;163(3):204-10. PubMed PMID: 16339053.
214. Monto AS. Antivirals for influenza in healthy adults. *Lancet.* 2006 May 13;367(9522):1571-2; author reply 1573. PubMed PMID: 16698401.
215. Victor JC, Surdina TY, Suleimeova SZ, Favorov MO, Bell BP, Monto AS. The increasing prominence of household transmission of hepatitis A in an area undergoing a shift in endemicity. *Epidemiol Infect.* 2006 Jun;134(3):492-7. PubMed PMID: 16194291; PubMed Central PMCID: PMC2870411.
216. Monto AS, McKimm-Breschkin JL, Macken C, Hampson AW, Hay A, Klimov A, Tashiro M, Webster RG, Aymard M, Hayden FG, Zambon M. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. *Antimicrob Agents Chemother.* 2006 Jul;50(7):2395-402. PubMed PMID: 16801417; PubMed Central PMCID: PMC1489772.
217. Ohmit SE, Monto AS. Symptomatic predictors of influenza virus positivity in children during the influenza season. *Clin Infect Dis.* 2006 Sep 1;43(5):564-8. PubMed PMID: 16886147.
218. Yen HL, Hoffmann E, Taylor G, Scholtissek C, Monto AS, Webster RG, Govorkova EA. Importance of neuraminidase active-site residues to the neuraminidase inhibitor resistance of influenza viruses. *J Virol.* 2006 Sep;80(17):8787-95. PubMed PMID: 16912325; PubMed Central PMCID: PMC1563878.
219. Walter EB, Neuzil KM, Zhu Y, Fairchok MP, Gagliano ME, Monto AS, Englund JA. Influenza vaccine immunogenicity in 6- to 23-month-old children: are identical antigens necessary for priming?. *Pediatrics.* 2006 Sep;118(3):e570-8. PubMed PMID: 16950948.
220. Englund JA, Walter EB, Gbadebo A, Monto AS, Zhu Y, Neuzil KM. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers. *Pediatrics.* 2006 Sep;118(3):e579-85. PubMed PMID: 16950949.
221. Whitley RJ, Monto AS. Prevention and treatment of influenza in high-risk groups: children, pregnant women, immunocompromised hosts, and nursing home residents. *J Infect Dis.* 2006 Nov 1;194 Suppl 2:S133-8. PubMed PMID: 17163386.
222. Whitley RJ, Bartlett J, Hayden FG, Pavia AT, Tapper M, Monto AS. Seasonal and pandemic influenza: recommendations for preparedness in the United States. *J Infect Dis.* 2006 Nov 1;194 Suppl 2:S155-61. PubMed PMID: 17163389.

223. Whitley RJ, Monto AS. Seasonal and pandemic influenza preparedness: a global threat. *J Infect Dis.* 2006 Nov 1;194 Suppl 2:S65-9. PubMed PMID: 17163390.
224. Monto AS, Comanor L, Shay DK, Thompson WW. Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness. *J Infect Dis.* 2006 Nov 1;194 Suppl 2:S92-7. PubMed PMID: 17163395.
225. Markel H, Stern AM, Navarro JA, Michalsen JR, Monto AS, DiGiovanni C. Nonpharmaceutical influenza mitigation strategies, US communities, 1918-1920 pandemic. *Emerg Infect Dis.* 2006 Dec;12(12):1961-4. PubMed PMID: 17326953; PubMed Central PMCID: PMC3291356.
226. Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, Rangarajan B, Newton DW, Boulton ML, Monto AS. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. *N Engl J Med.* 2006 Dec 14;355(24):2513-22. PubMed PMID: 17167134; NIHMSID: NIHMS76193; PubMed Central PMCID: PMC2614682.
227. Halloran ME, Hayden FG, Yang Y, Longini IM Jr, Monto AS. Antiviral effects on influenza viral transmission and pathogenicity: observations from household-based trials. *Am J Epidemiol.* 2007 Jan 15;165(2):212-21. PubMed PMID: 17088311.
228. Victor JC, Monto AS, Surdina TY, Suleimenova SZ, Vaughan G, Nainan OV, Favorov MO, Margolis HS, Bell BP. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. *N Engl J Med.* 2007 Oct 25;357(17):1685-94. PubMed PMID: 17947390.
229. Monto AS, Whitley RJ. Seasonal and pandemic influenza: a 2007 update on challenges and solutions. *Clin Infect Dis.* 2008 Apr 1;46(7):1024-31. PubMed PMID: 18444819.
230. Ohmit SE, Victor JC, Teich ER, Truscon RK, Rotthoff JR, Newton DW, Campbell SA, Boulton ML, Monto AS. Prevention of symptomatic seasonal influenza in 2005-2006 by inactivated and live attenuated vaccines. *J Infect Dis.* 2008 Aug 1;198(3):312-7. PubMed PMID: 18522501; NIHMSID: NIHMS76196; PubMed Central PMCID: PMC2613648.
231. Monto AS. Editorial commentary: viral susceptibility and the choice of influenza antivirals. *Clin Infect Dis.* 2008 Aug 1;47(3):346-8. PubMed PMID: 18582205.
232. Monto AS. Epidemiology of influenza. *Vaccine.* 2008 Sep 12;26 Suppl 4:D45-8. PubMed PMID: 19230159.
233. Jennings LC, Monto AS, Chan PK, Szucs TD, Nicholson KG. Stockpiling prepandemic influenza vaccines: a new cornerstone of pandemic preparedness plans. *Lancet Infect Dis.* 2008 Oct;8(10):650-8. PubMed PMID: 18922487.
234. Monto AS. Antivirals and influenza: frequency of resistance. *Pediatr Infect Dis J.* 2008 Oct;27(10 Suppl):S110-2. PubMed PMID: 18820569.
235. Monto AS. The risk of seasonal and pandemic influenza: prospects for control. *Clin Infect Dis.* 2009 Jan 1;48 Suppl 1:S20-5. PubMed PMID: 19067611.
236. Ohmit SE, Gross J, Victor JC, Monto AS. Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccination. *Vaccine.* 2009 Feb 11;27(7):1050-4. PubMed PMID: 19095028; NIHMSID: NIHMS95764; PubMed Central PMCID: PMC2665993.
237. Monto AS. Implications of antiviral resistance of influenza viruses. *Clin Infect Dis.* 2009 Feb 15;48(4):397-9. PubMed PMID: 19586376.
238. Layne SP, Monto AS, Taubenberger JK. Pandemic influenza: an inconvenient mutation. *Science.* 2009 Mar 20;323(5921):1560-1. PubMed PMID: 19299601; NIHMSID: NIHMS156509; PubMed Central PMCID: PMC2778479.

239. Monto AS, Ohmit SE. Seasonal influenza vaccines: evolutions and future trends. *Expert Rev Vaccines*. 2009 Apr;8(4):383-9. PubMed PMID: 19348555.
240. Uyeki TM, Prasad R, Vukotich C, Stebbins S, Rinaldo CR, Ferng YH, Morse SS, Aiello AE, Davis B, Monto AS. Low sensitivity of rapid diagnostic test for influenza. *Clin Infect Dis*. 2009 May 1;48(9):e89-92. PubMed PMID: 19323628.
241. Monto AS, Ansaldi F, Aspinall R, McElhaney JE, Montaña LF, Nichol KL, Puig-Barbera J, Schmitt J, Stephenson I. Influenza control in the 21st century: Optimizing protection of older adults. *Vaccine*. 2009 Aug 13;27(37):5043-53. PubMed PMID: 19559118.
242. Monto AS, Ohmit SE, Petrie JG, Johnson E, Truscon R, Teich E, Rotthoff J, Boulton M, Victor JC. Comparative efficacy of inactivated and live attenuated influenza vaccines. *N Engl J Med*. 2009 Sep 24;361(13):1260-7. PubMed PMID: 19776407.
243. Aiello AE, Murray GF, Perez V, Coulborn RM, Davis BM, Uddin M, Shay DK, Waterman SH, Monto AS. Mask use, hand hygiene, and seasonal influenza-like illness among young adults: a randomized intervention trial. *J Infect Dis*. 2010 Feb 15;201(4):491-8. PubMed PMID: 20088690.
244. Vukotich CJ Jr, Coulborn RM, Aragon TJ, Baker MG, Burrus BB, Aiello AE, Cowling BJ, Duncan A, Enanoria W, Fabian MP, Ferng YH, Larson EL, Leung GM, Markel H, Milton DK, Monto AS, Morse SS, Navarro JA, Park SY, Priest P, Stebbins S, Stern AM, Uddin M, Wetterhall SF. Findings, gaps, and future direction for research in nonpharmaceutical interventions for pandemic influenza. *Emerg Infect Dis*. 2010 Apr;16(4):e2. PubMed PMID: 20350370.
245. Aiello AE, Coulborn RM, Aragon TJ, Baker MG, Burrus BB, Cowling BJ, Duncan A, Enanoria W, Fabian MP, Ferng YH, Larson EL, Leung GM, Markel H, Milton DK, Monto AS, Morse SS, Navarro JA, Park SY, Priest P, Stebbins S, Stern AM, Uddin M, Wetterhall SF, Vukotich CJ Jr. Research findings from nonpharmaceutical intervention studies for pandemic influenza and current gaps in the research. *Am J Infect Control*. 2010 May;38(4):251-8. PubMed PMID: 20226569.
246. Uddin M, Cherkowski GC, Liu G, Zhang J, Monto AS, Aiello AE. Demographic and socioeconomic determinants of influenza vaccination disparities among university students. *J Epidemiol Community Health*. 2010 Sep;64(9):808-13. PubMed PMID: 19828514.
247. Carney PJ, Lipatov AS, Monto AS, Donis RO, Stevens J. Flexible label-free quantitative assay for antibodies to influenza virus hemagglutinins. *Clin Vaccine Immunol*. 2010 Sep;17(9):1407-16. PubMed PMID: 20660137; PubMed Central PMCID: PMC2944469.
248. Monto AS. Seasonal influenza vaccinations: specialized products for different target groups. *Vaccine*. 2010 Sep 7;28 Suppl 4:D14-23. PubMed PMID: 20713256.
249. Monto AS. Seasonal influenza and vaccination coverage. *Vaccine*. 2010 Sep 7;28 Suppl 4:D33-44. PubMed PMID: 20713259.
250. Griffin MR, Monto AS, Belongia EA, Treanor JJ, Chen Q, Chen J, Talbot HK, Ohmit SE, Coleman LA, Lofthus G, Petrie JG, Meece JK, Hall CB, Williams JV, Gargiullo P, Berman L, Shay KL. Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 US communities. *PLoS One*. 2011;6(8):e23085. PubMed PMID: 21857999; PubMed Central PMCID: PMC3155536.
251. Petrie JG, Ohmit SE, Johnson E, Cross RT, Monto AS. Efficacy studies of influenza vaccines: effect of end points used and characteristics of vaccine failures. *J Infect Dis*. 2011 May 1;203(9):1309-15. PubMed PMID: 21378375; PubMed Central PMCID: PMC3069734.
252. Monto AS, Black S, Plotkin SA, Orenstein WA. Response to the 2009 pandemic: effect on influenza

- control in wealthy and poor countries. *Vaccine*. 2011 Sep 2;29(38):6427-31. PubMed PMID: 21763381.
253. Ohmit SE, Petrie JG, Cross RT, Johnson E, Monto AS. Influenza hemagglutination-inhibition antibody titer as a correlate of vaccine-induced protection. *J Infect Dis*. 2011 Dec 15;204(12):1879-85. PubMed PMID: 21998477.
254. Aiello AE, Perez V, Coulborn RM, Davis BM, Uddin M, Monto AS. Facemasks, hand hygiene, and influenza among young adults: a randomized intervention trial. *PLoS One*. 2012;7(1):e29744. PubMed PMID: 22295066; PubMed Central PMCID: PMC3266257.
255. Ampofo WK, Baylor N, Cobey S, Cox NJ, Daves S, Edwards S, Ferguson N, Grohmann G, Hay A, Katz J, Kullabutr K, Lambert L, Levandowski R, Mishra AC, Monto AS, Siqueira M, Taxhiro M, Waddell AL, Wairagkar N, Wood J, Zambon M, Shang W. Improving influenza vaccine virus selection: report of a WHO informal consultation held at WHO headquarters, Geneva, Switzerland, 14-16 June 2010. *Influenza Other Respir Viruses*. 2012 Mar;6(2):142-52, e1-5. PubMed PMID: 21819547.
256. Van Kerkhove MD, Riley S, Lipsitch M, Guan Y, Monto AS, Webster RF, Zambon M, Nicoll A, Peiris JS, Ferguson NM. Comment on "Seroevidence for H5N1 influenza infections in humans: meta-analysis". *Science*. 2012 Jun 22;336(6088):1506; author reply 1506. PubMed PMID: 22723396.
257. Perez V, Uddin M, Galea S, Monto AS, Aiello AE. Stress, adherence to preventive measures for reducing influenza transmission and influenza-like illness. *J Epidemiol Community Health*. 2012 Jul;66(7):605-10. PubMed PMID: 21224242.
258. Graitcer SB, Dube NL, Basurto-Davila R, Smith PF, Ferdinands J, Thompson M, Uzzicanin A, Gargiullo P, Chaves SS, Robinson S, Sears S, Tipton M, Monto AS, Mills D, Shay DK. Effects of immunizing school children with 2009 influenza A (H1N1) monovalent vaccine on absenteeism among students and teachers in Maine. *Vaccine*. 2012 Jul 6;30(32):4835-41. PubMed PMID: 22609012.
259. Monto AS, Ohmit SE. Editorial commentary: seasonal influenza vaccines during the 2009 pandemic: help or harm? *Clin Infect Dis*. 2012 Sep;55(5):703-5. PubMed PMID: 22670047.
260. Treanor JJ, Talbot HK, Ohmit SE, Coleman LA, Thompson MG, Cheng PY, Petrie JG, Lofthus G, Meece JK, Williams JV, Berman L, Breese Hall D, Monto AS, Griffin MR, Belongia E, Shay DK, US Flu-VE Network. Effectiveness of seasonal influenza vaccines in the United States during a season with circulation of all three vaccine strains. *Clin Infect Dis*. 2012 Oct;55(7):951-9. PubMed PMID: 22843783; PubMed Central PMCID: PMC3657521.
261. Uzzicanin A, Thompson M, Smith P, Chaves SS, Foster L, Dube N, Graitcer S, Jackson R, Ferdinands J, Gargiullo P, Mills D, Monto AS, Shay DK. Effectiveness of 1 dose of influenza A (H1N1) 2009 monovalent vaccines in preventing reverse-transcription polymerase chain reaction-confirmed H1N1 infection among school-aged children in Maine. *J Infect Dis*. 2012 Oct 1;206(7):1059-68. PubMed PMID: 22850120.
262. Petrie JG, Ohmit SE, Cowling BJ, Johnson E, Cross RT, Malosh RE, Thompson MG, Monto AS. Influenza transmission in a cohort of households with children: 2010-2011. *PLoS One*. 2013;8(9):e75339. PubMed PMID: 24086511; PubMed Central PMCID: PMC3783407.
263. Monto AS, Webster RG. *Textbook of Influenza*. 2nd ed. Webster RG, Monto AS, Braciale TJ, Lamb RA, editors. Chichester, UK: Wiley & Sons, Ltd; 2013. Influenza pandemics: History and lessons learned; p.20-33.
264. Widdowson MA, Monto AS. *Textbook of Influenza*. 2nd ed. Webster RG, Monto AS, Braciale TJ, Lamb RA, editors. Chichester, UK: Wiley & Sons, Ltd; 2013. Epidemiology of influenza; p.250-65.
265. Monto AS. *Pandemic Influenza*. 2nd ed. Van-Tam J, Sellwood C, editors. Wallingford, UK: CAB

- International; 2013. History and epidemiological features of pandemic influenza; p.40-8.
266. Whitley RJ, Boucher CA, Lina B, Nguyen-Van-Tam JS, Osterhaus A, Schutten M, Monto AS. Global assessment of resistance to neuraminidase inhibitors, 2008-2011: the Influenza Resistance Information Study (IRIS). *Clin Infect Dis*. 2013 May;56(9):1197-205. PubMed PMID: 23307766.
267. Ohmit SE, Petrie JG, Malosh RE, Cowling BJ, Thompson MG, Shay DK, Monto AS. Influenza vaccine effectiveness in the community and the household. *Clin Infect Dis*. 2013 May;56(10):1363-9. PubMed PMID: 23413420; PubMed Central PMCID: PMC3693492.
268. Gessner BD, Brooks WA, Neuzil KM, Vernet G, Bright RA, Tam JS, Bresee J, Monto AS. Vaccines as a tool to estimate the burden of severe influenza in children of low-resourced areas (November 30-December 1, 2012, Les Pensieres, Veyrier-du-Lac, France). *Vaccine*. 2013 Jul 11;31(32):3222-8. PubMed PMID: 23707161.
269. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus ADME. Cochrane re-arranged: support for policies to vaccinate elderly people against influenza. *Vaccine*. 2013 Dec 5;31(50):6030-3. PubMed PMID: 24095882.
270. Monto AS, Cowling BC, Peris J. *Viral Infections of Humans: Epidemiology and Control*. 5th ed. Kaslow RA, Stanberry LR, Le Duc JW, editors. New York: Springer Science & Business Media; 2014. Coronaviruses; p.199-223.
271. Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, Jackson L, Meece JL, Nowalk MP, Song J, Zervos M, Cheng PY, Rinaldo CR, Clipper L, Shay KL, Piegra P, Monto AS. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. *Clin Infect Dis*. 2014 Feb;58(3):319-27. PubMed PMID: 24235265; PubMed Central PMCID: PMC4007111.
272. Flannery B, Thaker SN, Clippard J, Monto AS, Ohmit SE, Zimmerman RK, Nowalk MP, Gaglani M, Jackson ML, Jackson LA, Belongia EA, McLean HQ, Berman L, Foust A, Sessions W, Spencer S, Fray AM. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness - United States, February 2014. *MMWR Morb Mortal Wkly Rep*. 2014 Feb 21;63(7):137-42. PubMed PMID: 24553196.
273. Malosh R, Ohmit SE, Petrie JG, Thompson MG, Aiello AE, Monto AS. Factors associated with influenza vaccine receipt in community dwelling adults and their children. *Vaccine*. 2014 Apr 1;32(16):1841-7. PubMed PMID: 24530926; NIHMSID: NIHMS600968; PubMed Central PMCID: PMC4084780.
274. Havers F, Thaker S, Clippard JR, Jackson M, McLean HQ, Gaglani M, Monto AS, Zimmerman RK, Jackson L, Petrie JG, Nowalk MP, Moehling KK, Glannery B, Thompson MG, Fry AM. Use of influenza antiviral agents by ambulatory care clinicians during the 2012-2013 influenza season. *Clin Infect Dis*. 2014 Sep 15;59(6):774-82. PubMed PMID: 25034419; PubMed Central PMCID: PMC4200045.
275. Monto AS, Malosh RE, Petrie JG, Thompson MG, Ohmit SE. Frequency of acute respiratory illnesses and circulation of respiratory viruses in households with children over 3 surveillance seasons. *J Infect Dis*. 2014 Dec 1;210(11):1792-9. PubMed PMID: 24907381; PubMed Central PMCID: PMC4296188.
276. de Jong MD, Ison MG, Monto AS, Metev H, Clark C, O'Neil B, Elder J, McCullough A, Collis P, Sheridan WP. Evaluation of intravenous peramivir for treatment of influenza in hospitalized patients. *Clin Infect Dis*. 2014 Dec 15;59(12):e172-85. PubMed PMID: 25115871.
277. Beyer WE, McElhaney J, Smith DJ, Monto AS, Nguyen-Van-Tam JS, Osterhaus AD. Reply: Letter to the editor, Cochrane rearranged. *Vaccine*. 2015 Jan 1;33(1):13-4. PubMed PMID: 24852718.
278. Flannery B, Clippard J, Zimmerman RK, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Petrie JG,

- McLean HQ, Belongia EA, Gaglani M, Berman L, Foust A, Sessions W, Thaker SN, Spencer S, Fry AM. Early estimates of seasonal influenza vaccine effectiveness - United States, January 2015. *MMWR Morb Mortal Wkly Rep.* 2015 Jan 16;64(1):10-5. PubMed PMID: 25590680.
279. Dobson J, Whitley RJ, Pocock S, Monto AS. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. *Lancet.* 2015 May 2;385(9979):1729-37. PubMed PMID: 25640810.
280. Ohmit SE, Petrie JG, Malosh RE, Fry AM, Thompson MG, Monto AS. Influenza vaccine effectiveness in households with children during the 2012-2013 season: assessments of prior vaccination and serologic susceptibility. *J Infect Dis.* 2015 May 15;211(10):1519-28. PubMed PMID: 25416812; PubMed Central PMCID: PMC4462665.
281. McLean HQ, Thompson MG, Sundaram ME, Kieke BA, Gaglani M, Murthy K, Piedra PA, Zimmerman RK, Nowalk MP, Raviotta JM, Jackson ML, Jackson L, Ohmit SE, Petrie JG, Monto AS, Meece JK, Thaker SN, Clippard JR, Spencer SM, Fry AM, Belongia EA. Influenza vaccine effectiveness in the United States during 2012-2013: variable protection by age and virus type. *J Infect Dis.* 2015 May 15;211(10):1529-40. PubMed PMID: 25406334; PubMed Central PMCID: PMC4407759.
282. Petrie JG, Ohmit SE, Johnson E, Truscon R, Monto AS. Persistence of antibodies to influenza hemagglutinin and neuraminidase following one or two years of influenza vaccination. *J Infect Dis.* 2015 May 26;PubMed PMCID: PMC4655854.
283. Havers F, Flannery B, Clippard JR, Gaglani M, Zimmerman RK, Jackson LA, Petrie JG, McLean HQ, Nowalk MP, Jackson ML, Monto AS, Belongia EA, Eng HF, Lamerato L, Campbell AP, Fry AM. Use of influenza antiviral medications among outpatients at high risk for influenza-associated complications during the 2013-2014 influenza season. *Clin Infect Dis.* 2015 Jun 1;60(11):1677-80. PubMed PMID: 25722198; PubMed Central PMCID: PMC4542604.
284. Davis BM, Markel H, Navarro A, Wells E, Monto AS, Wells E, Monto AS, Aiello AE. The effect of reactive school closure on community influenza-like illness counts in the state of Michigan during the 2009 H1N1 pandemic. *Clin Infect Dis.* 2015 Jun 15;60(12):e90-7. PubMed PMID: 25896795.
285. Jackson ML, Jackson LA, McClure D, Gaglani M, Murthy K, Malosh R, Monto A, Zimmerman RK, Foppa IM, Flannery B, Thompson MG. Incidence of medically attended influenza infection and cases averted by vaccination, 2011/2012 and 2012/2013 influenza seasons. *Vaccine.* 2015 Sep 22;33:5181-7. PMCID: 26271827.
286. Monto AS, Petrie JG, Cross RT, Johnson E, Liu M, Zhong W, Levine M, Katz JM, Ohmit SE. Antibody to influenza virus neuraminidase: an independent correlate of protection. *J Infect Dis.* 2015 Oct 15;212:1191-9. PMID: 25858957.
287. van Essen GE, Openshaw P, Myles P, Monto A, van der Vries E. Conference Report. How should influenza be treated? Focus on antivirals. *Vaccine* 2015 Dec 8;33:7033-6. PMID: 26256525
288. Petrie JG, Cheng C, Malosh RE, VanWormer JJ, Flannery B, Zimmerman RK, Gaglani M, Jackson ML, King JP, Nowalk MP, Benoit J, Robertson A, Thaker SN, Monto AS, Ohmit SE. Illness Severity and Work Productivity Loss Among Working Adults With Medically Attended Acute Respiratory Illnesses: US Influenza Vaccine Effectiveness Network 2012-2013. *Clin Infect Dis.* 2016 Feb 15;62:448-55. PMCID: PMC4725387.
289. Ohmit SE, Petrie JG, Malosh RE, Johnson E, Truscon R, Aaron B, Martens C, Cheng C, Fry AM, Monto AS. Substantial Influenza Vaccine Effectiveness in Households With Children During the 2013-2014 Influenza Season, When 2009 Pandemic Influenza A(H1N1) Virus Predominated. *J Infect Dis.* 2016 Apr 15;213:1229-36. PMCID: PMC4799665.

290. Thompson MG, Clippard J, Petrie JG, Jackson ML, McLean HQ, Gaglani M, Reis EC, Flannery B, Monto AS, Jackson L, Belongia EA, Murthy K, Zimmerman RK, Thaker S, Fry AM. Influenza Vaccine Effectiveness for Fully and Partially Vaccinated Children 6 months to 8 Years Old during 2011-2012 and 2012-2013: The Importance of Two Priming Doses. *Pediatr Infect Dis J*. 2016 Mar;35:299-308. PMID: PMC5218633.
291. Chung JR, Flannery B, Thompson MG, Gaglani M, Jackson ML, Monto AS, Nowalk MP, Talbot HK, Treanor JJ, Belongia EA, Murthy K, Jackson LA, Petrie JG, Zimmerman RK, Griffin MR, McLean HQ, Fry AM. Seasonal Effectiveness of Live Attenuated and Inactivated Influenza Vaccine. *Pediatrics*. 2016 Feb;137:e20153279. PMID: PMC4732363.
292. Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, Chung JR, Piedra PA, Avadhanula V, Nowalk MP, Zimmerman RK, Jackson ML, Jackson LA, Petrie JG, Ohmit SE, Monto AS, McLean HQ, Belongia EA, Fry AM, Flannery B. Influenza Vaccine Effectiveness Against 2009 Pandemic Influenza A(H1N1) Virus Differed by Vaccine Type During 2013-2014 in the United States. *J Infect Dis*. 2016 213:1546-56. PMID: PMC4837903.
293. Zhao X, Fang VJ, Ohmit SE, Monto AS, Cook AR, Cowling BJ. Quantifying Protection Against Influenza Virus Infection Measured by Hemagglutination-inhibition Assays in Vaccine Trials. *Epidemiology*. 2016 Jan;27:143-51. PMID: PMC4658669.
294. Petrie JG, Ohmit SE, Truscon R, Johnson E, Braun TM, Levine MZ, Eichelberger MC, Monto AS. Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007-2008 Influenza Season. *J Infect Dis*. 2016 Oct 15;214:1142-9. PMID:27095420.
295. Aiello AE, Simanek AM, Eisenberg MC, Walsh AR, Davis B, Volz E, Cheng C, Rainey JJ, Uzicanin A, Gao H, Osgood N, Knowles D, Stanley K, Tarter K, Monto AS. Design and methods of a social network isolation study for reducing respiratory infection transmission: The ex-flu cluster randomized trial. *Epidemics* 2016 June;15:38-55. PMID: PMC5903923.
296. Flannery B, Zimmerman RK, Gubareva LV, Garten RJ, Chung JR, Nowalk MP, Jackson ML, Jackson LA, Monto AS, Ohmit SE, Belongia EA, McLean HQ, Gaglani M, Piedra PA, Mishin VP, Chesnokov AP, Spencer S, Thaker SN, Barnes JR, Foust A, Sessions W, Xu X, Katz J, Fry AM. Enhanced genetic characterization of influenza A(H3N2) viruses and vaccine effectiveness by genetic group, 2014-2015. *J Infect Dis* 2016 Oct 1;214:1010-19. PMID: 27190176
297. Petrie JG, Ohmit SE, Cheng CK, Martin E T, Malosh RE, Luring AS, Lamerato LE, Reyes KC, Flannery B, Ferdinands JM, Monto AS. Influenza Vaccine Effectiveness against Antigenically Drifted Influenza Higher than Expected in Hospitalized Adults: 2014-2015. *Clin Infect Dis*. 2016 Oct 15;63:1017-25. PMID: 27369320.
298. Zimmerman RK, Balasubramani GK, Nowalk MP, Eng H, Urbanski L, Jackson ML, Jackson LA, McLean HQ, Belongia EA, Monto AS, Malosh RE, Gaglani M, Clipper L, Flannery B, Wisniewski SR. Classification and Regression Tree (CART) analysis to predict influenza in primary care patients *BMC Infect Dis*. 2016 Sep 22;16:503. PMID: PMC5034457.
299. Zimmerman RK, Nowalk MP, Chung J, Jackson ML, Jackson LA, Petrie JG, Monto AS, McLean HQ, Belongia EA, Gaglani M, Murthy K, Fry AM, Flannery B. 2014-2015 Influenza Vaccine Effectiveness in the United States by Vaccine Type. *Clin Infect Dis* 2016. PMID: PMC5146719. [Epub ahead of print]
300. Petrie, J. G., Parkhouse, K., Ohmit, S. E., Malosh, R. E., Monto, A. S., & Hensley, S. E. (2016). Antibodies Against the Current Influenza A(H1N1) Vaccine Strain Do Not Protect Some Individuals From Infection With Contemporary Circulating Influenza A(H1N1) Virus Strains. *J Infect Dis*, 2016

Dec 15;214(12):1947-51. Epub 2016 Oct 7. PMID: PMC5142093

301. Debbink, K., McCrone, J.T., Petrie, J.G., Truscon, R., Johnson, E., Mantlo, E.K., Monto, A.S., Luring, A.S. (2017). Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses. *PLoS pathog*, 2017 Jan 31;13(1): e1006194. PMID: PMC5302840
302. Petrie, J. G. and A. S. Monto (2017). Untangling the Effects of Prior Vaccination on Subsequent Influenza Vaccine Effectiveness. *J Infect Dis*, 2017 Mar 15;215(6): 841-843. Epub 2017 Feb 7. PMID: 28453852\
303. Flannery, B., Chung, J.R., Thacker, S.N., Monto, A.S., Martin, E.T., Belongia, E.A., McLean, H.Q., Gaglani, M., Murthy, K., Zimmerman, R.K., Nowalk, M.P., Jackson, M.L., Jackson, L.A., Foust, A., Sessions, W., Berman, L., Spencer, S., Fry, A.M. (2017). Interim Estimates of 2016-17 Seasonal Influenza Vaccine Effectiveness - United States, February 2017. *MMWR. Morb mortality wkly rep*, 2017 Feb 17;66(6): 167-171. PMID: 28207689
304. Monto, A. S. (2017). Moving Toward Improved Influenza Vaccines. *J Infect Dis*, 2017 Feb 15;215(4): 500-502. Epub 2017 Mar 2. PMID: 28329073
305. Fell, D. B., Bhutta, Z.A., Hutcheon, J.A., Karron, R.A., Knight, M., Kramer, M.S., Monto, A.S., Swamy, G.K., Ortiz, J.R., Savitz, D.A. (2017). Report of the WHO technical consultation on the effect of maternal influenza and influenza vaccination on the developing fetus: Montreal, Canada, September 30-October 1, 2015. *Vaccine*, 2017 Apr 25;35(18): 2279-2287. Epub 2017 March 24. PMID: 28343772
306. Monto, A. S., Malosh, R.E., Petrie, J.G., Martin, E.T. (2017). The doctrine of original antigenic sin: separating good from evil. *J Infect Dis*, 2017. PMID: 28398521. [Epub ahead of print]